Literature DB >> 23271169

Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis.

Sonosuke Yukawa1, Kunihiro Yamaoka, Norifumi Sawamukai, Shohei Shimajiri, Satoshi Kubo, Ippei Miyagawa, Koshiro Sonomoto, Kazuyoshi Saito, Yoshiya Tanaka.   

Abstract

BACKGROUND: Systemic sclerosis (SSc) is characterized by skin sclerosis, which develops from the distal extremities and spreads to the trunk. Although several reports have implied the involvement of mast cells in SSc based on examination of forearm skin specimens, there have been no studies that examined digital skin specimens.
METHODS: Skin biopsies were obtained from the distal one-third of the forearm and between distal and proximal interphalangeal joints from 46 SSc patients, as well as from 29 non-SSc patients and normal controls. Dermal mast cells were detected histologically using NanoZoomer digital pathology.
RESULTS: Dermal mast cell density was significantly higher in both the forearms and fingers in SSc patients compared with non-SSc patients and normal controls. Digital dermal mast cell density was significantly higher in patients with diffuse cutaneous SSc than in local cutaneous SSc patients and also in the anti-topoisomerase I antibody-positive group than in the negative group, though such tendency was not noted in the forearm dermis. Interestingly, digital dermal mast cell density tended to correlate negatively but significantly with disease duration, suggesting the possible involvement of dermal mast cells in the early pathological process.
CONCLUSION: Digital accumulation of toluidine blue- and/or c-Kit-positive dermal mast cells appears to be involved in the early stages of the pathological processes of SSc, especially in patients positive for anti-topoisomerase I antibody.

Entities:  

Mesh:

Year:  2012        PMID: 23271169     DOI: 10.1007/s10165-012-0813-8

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  7 in total

Review 1.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

Review 2.  Innate Immunity in Systemic Sclerosis.

Authors:  Christopher Dowson; Nathan Simpson; Laura Duffy; Steven O'Reilly
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.592

Review 3.  Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.

Authors:  Theodoros-Ioannis Papadimitriou; Arjan van Caam; Peter M van der Kraan; Rogier M Thurlings
Journal:  Biomedicines       Date:  2022-01-29

Review 4.  The role of type 1 interferon in systemic sclerosis.

Authors:  Minghua Wu; Shervin Assassi
Journal:  Front Immunol       Date:  2013-09-06       Impact factor: 7.561

5.  Mastocytosis and systemic sclerosis: a clinical association.

Authors:  Gianluca Bagnato; William Neal Roberts; Davide Sciortino; Donatella Sangari; Santa Cirmi; Roneka L Ravenell; Michele Navarra; Gianfilippo Bagnato; Sebastiano Gangemi
Journal:  Clin Mol Allergy       Date:  2016-10-11

6.  An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis.

Authors:  Takashi Yamashita; Katja Lakota; Takashi Taniguchi; Ayumi Yoshizaki; Shinichi Sato; Wen Hong; Xingchun Zhou; Snezn Sodin-Semrl; Feng Fang; Yoshihide Asano; John Varga
Journal:  Sci Rep       Date:  2018-08-07       Impact factor: 4.379

Review 7.  Innate Immunity in Systemic Sclerosis Fibrosis: Recent Advances.

Authors:  Paoline Laurent; Vanja Sisirak; Estibaliz Lazaro; Christophe Richez; Pierre Duffau; Patrick Blanco; Marie-Elise Truchetet; Cécile Contin-Bordes
Journal:  Front Immunol       Date:  2018-07-23       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.